Cardiac Toxicity Associated with the Anti-VEGF Monoclonal Antibody Bevacizumab (Avastin) in Combination with CROP (A-CHOP) Chemotherapy for Peripheral T Cell Lymphoma (PTCL): The ECOG 2404 Trial.

被引:5
|
作者
Advani, Ranjana H. [1 ]
Hong, Fangxin [2 ]
Ganjoo, Kristen N. [3 ]
Manola, Judith B. [2 ]
Swinnen, Lode J. [4 ]
Habermann, Thomas M. [5 ]
Horning, Sandra J. [1 ]
机构
[1] Stanford Univ, Stanford, CA 94305 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Stanford Univ, Palo Alto VAHCS, Palo Alto, CA 94304 USA
[4] Johns Hopkins Canc Ctr, Div Hem Malignancy, Baltimore, MD USA
[5] Mayo Clin, Coll Med, Rochester, MN USA
关键词
D O I
10.1182/blood.V114.22.1671.1671
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:667 / 667
页数:1
相关论文
共 2 条
  • [1] Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial
    Advani, Ranjana H.
    Hong, Fangxin
    Horning, Sandra J.
    Kahl, Brad S.
    Manola, Judith
    Swinnen, Lode J.
    Habermann, Thomas M.
    Ganjoo, Kristen
    LEUKEMIA & LYMPHOMA, 2012, 53 (04) : 718 - 720
  • [2] Humanized ANTI-VEGF monoclonal antibody (Bevacizumab) therapy in combination with chemotherapy - A new option for Hodgkin Lymphoma treatment?
    Reiners, K. S.
    von Tresckow, B.
    von Strandmann, E. Pogge
    Hansen, H. P.
    Rothe, A.
    Boell, B.
    Engert, A.
    Borchmann, P.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 63 - 63